Title: Real-life performance of mepolizumab in T2-high severe refractory asthma with the overlapping eosinophilic-allergic phenotype.
Citation: Biomedicines
2022;10:2635.
Country: Spain | Indication: Asthma
http://tago.ca/36289896
Title: Real-life performance of mepolizumab in T2-high severe refractory asthma with the overlapping eosinophilic-allergic phenotype.
Citation: Biomedicines
2022;10:2635.
Country: Spain | Indication: Asthma
Title: Real-life performance of mepolizumab in T2-high severe refractory asthma with the overlapping eosinophilic-allergic phenotype.
Citation: Biomedicines
2022;10:2635.
Country: Spain | Indication: Asthma